This Sources Sought opportunity from Department Of Defense was posted on August 20, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Coagulation Analyzer System

Closed

FA860126Q0136SSFederal

Submission Closed08/25/2026, 04:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

International

Pralidoxime Chloride/Methyl Sulfate ManufacturingThis subcontract involves the manufacture and supply of Pralidoxime chloride or methyl sulfate in solution or powder form for injection to support prime contractors on Department of National Defence projects. The required product must have a dosage strength of at least 200 mg per container and a minimum shelf-life of 36 months. The selected provider is responsible for conducting stability testing, providing quality assurance certification, and delivering complete treatment courses along with stability reports and product monographs. To be eligible, the manufacturer must hold a Health Canada Notice of Compliance under Division 8 or Division 11 authorization. This global procurement opportunity is managed by the Government of Canada and allows for performance across various international regions. Interested parties must submit their responses by November 10, 2026.

Department of National Defence

POSTED

DEADLINE

SLS Printer Consumables and Maintenance KitsThis subcontract focuses on the provision of specialized consumables and wear-and-tear replacement parts to support prime contractors working on Department of National Defence projects for the Government of Canada. The scope of supply includes engineering-grade thermoplastic powders such as PA 11, PA 12, PP, and TPU, along with critical SLS hardware components including optical cassettes, recoater blades, infrared heaters, sealing foam gaskets, and build chambers. All bulk consumables and spare parts kits are to be delivered to CFB Petawawa. The opportunity was posted on October 20, 2026, with a response deadline of November 2, 2026, falling under NAICS code 325412.

Department of National Defence

POSTED

DEADLINE

Supplier of Red Sealing Compound (NSN 8030015650423)This subcontract involves the supply of red sealing compound, identified by NSN 8030015650423, for prime contractors working under the Defense Logistics Agency. The material must be provided in 10.00 milliliter containers and strictly adhere to the DLA Master List of Technical and Quality Requirements RA001. The supplier is responsible for managing TYPE I (CODE H) shelf-life requirements and ensuring all packaging complies with MIL-STD-2073-1E and MIL-STD-129 standards. Additionally, the contractor must provide all necessary safety documentation, including SDS and HazCom labels in accordance with 29 C.F.R. 1910.1200. The performance of this contract is centered in FPO 09591-0100, with the primary objective being the delivery of packaged sealing compound and its associated safety certifications to the Department of Defense.

Defense Logistics Agency

POSTED

DEADLINE

Active Pharmaceutical Ingredient (API) SupplyThis subcontract for Active Pharmaceutical Ingredient (API) Supply involves the synthesis, purification, and bulk delivery of pharmaceutical-grade Benzocaine and Menthol. The provider supports prime contractors fulfilling requirements for the Department of Defense Medical Supply Chain Pharm FSA, ensuring all raw chemical components meet strict USP and ISO manufacturing standards through the use of HPLC purity testing. The performance of this contract is centered at Fort Campbell, Kentucky, under NAICS code 325412. The solicitation was posted on October 19, 2026, with a response deadline of October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Benzocaine and Menthol Lozenge SupplyThis subcontract involves the manufacture and supply of finished Benzocaine and Menthol lozenges to prime contractors supporting the Department of Defense Medical Supply Chain Pharm FSA. The provider is responsible for producing and quality-testing pharmaceutical lozenges within FDA-compliant facilities adhering to Good Manufacturing Practice standards to ensure all delivered quantities meet strict government specifications. Administrative processes for this requirement are managed through the DLA Internet Bid Board System for quote submissions. The performance of the contract is centered at Fort Campbell, and the procurement falls under NAICS code 325412 for pharmaceutical preparation.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Moxifloxacin Hydrochloride Tablets (400 MG)This subcontract, managed by the Medical Supply Chain Pharm FSA under the Department of Defense, involves the manufacture and supply of pharmaceutical-grade Moxifloxacin Hydrochloride Tablets (400 MG). The contractor is responsible for providing the antibiotic tablets in 30-count bottles, ensuring all products are sourced or manufactured in accordance with Good Manufacturing Practices and FDA approval and registration requirements. Logistical compliance is critical, as the contract mandates adherence to RP001 DLA Packaging Requirements and the use of climate-controlled storage and transport to maintain product integrity. Performance will take place in FPO 09591, with the primary objective of supporting prime contractors on DLA supply contracts.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Activated Charcoal, SuspensionThis subcontract, issued by the Medical Supply Chain Pharm FSA under the Department of Defense, requires the provision of activated charcoal in suspension form, identified by NSN 6505012828880. The materials must be delivered to the USS Lewis B Puller ESB 3, with all shipments adhering to strict DLA packaging requirements and technical specifications. The contract falls under NAICS code 325412 and is intended for prime contractors supporting DLA supply operations. Resellers are specifically required to comply with the Non-Manufacturer Rule to ensure eligibility. The performance location is designated as FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of 4% Chlorhexidine Gluconate Surgical DetergentThis subcontract involves the supply of FDA-regulated 4% Chlorhexidine Gluconate surgical detergent for prime contractors supporting Department of Defense supply contracts. The provider is responsible for manufacturing or sourcing the chemical compound in strict accordance with NSN 6505-01-101-3759 specifications and DLA Packaging Requirements RP001. To maintain quality and regulatory compliance, the product must be produced in FDA-approved pharmaceutical manufacturing facilities. The contract mandates a total shelf life of 24 months, with a requirement that the detergent possesses at least 21 months of remaining shelf life at the time of delivery. Managed under the Medical Supply Chain Pharm FSA, the performance of this contract is centered in FPO 96660, falling under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Bupivacaine and Epinephrine InjectionThis subcontract involves the supply of Bupivacaine and Epinephrine Injection to prime contractors supporting DLA Troop Support medical supply contracts. The provider must deliver end items compliant with NSN 6505-01-189-3973, utilizing pharmaceutical-grade materials and medical-grade packaging. To qualify, the supplier is required to hold all necessary pharmaceutical manufacturing licenses and maintain FDA approval for the specific drug formulation. Managed by the Department of Defense under the Medical Supply Chain Pharm FSA, the contract specifies the delivery of injectable medication quantities as outlined in the award. The performance location is designated as FPO 09591, and the procurement falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Isoniazid Tablet ManufacturingThis subcontract involves the manufacturing of Isoniazid 300 MG tablets for prime contractors supporting Department of Defense pharmaceutical supply contracts through the Medical Supply Chain Pharm FSA. The manufacturer is responsible for producing tablets that conform to United States Pharmacopeia standards, packaged in bottles of 100 units. To execute this contract, the provider must utilize pharmaceutical grade API, specialized tablet pressing equipment, and a USP-compliant quality control laboratory. Strict regulatory adherence is required, including the maintenance of active FDA registration and continuous USP compliance. The performance of this contract is centered in FPO 09591, with the primary objective of delivering finished pharmaceutical products that meet all specified government quality and safety benchmarks.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Tetrahydrozoline Hydrochloride Ophthalmic Solution SupplierThis subcontract involves the supply of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (0.05%, 15 ML) to support prime contractors under DLA Troop Support medical supply contracts. The selected provider is responsible for manufacturing or sourcing the pharmaceutical solution in accordance with USP standards, utilizing sterile ophthalmic bottling and packaging. All operations must comply with FDA approval and registration requirements for pharmaceutical manufacturing. The contract is managed by the Department of Defense under the Medical Supply Chain Pharm FSA. Physical deliveries of the ophthalmic solution are to be made to either the prime contractor or the Naval Med Readiness Logistics Command, with the place of performance located in Williamsburg, Virginia.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Tolnaftate Powder, USP 1%This subcontract through the Department of Defense Medical Supply Chain Pharm FSA involves the supply of Tolnaftate Powder, USP 1%, to prime contractors on DLA Troop Support medical supply contracts. The requirement is for 15 bottles of 45 GM powder, identified by NSN 6505014807897, which must strictly adhere to USP 1% standards and the DLA Master List of Technical and Quality Requirements. Eligible providers must possess the necessary pharmaceutical manufacturing and distribution licenses to fulfill the order. The performance of this contract is designated for FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 6 days

AI Contract Overview

The United States Air Force, through the Air Force Life Cycle Management Center, has issued a sources sought synopsis to conduct market research for an Automated Coagulation Analyzer System for the Wright-Patterson Medical Center in Ohio. This notice is intended to identify potential sources capable of meeting the technical requirements and is not a formal request for proposals or a binding contract. The government is specifically looking to identify various business capabilities, including small businesses, 8(a) participants, HUBZone, women-owned, and service-disabled veteran-owned small businesses, to determine if a future solicitation should be conducted as a set-aside. Interested firms must submit a concise capabilities package, not exceeding five pages, that demonstrates technical compliance with the specified requirements. Submissions must be sent via email to the designated points of contact no later than August 25, 2026, at 12:00 PM EDT. Responses should include the firm's socio-economic status, any foreign ownership or control information, and details regarding the intended use of subcontractors. All prospective contractors must be registered in the System for Award Management (SAM) to be eligible for any future award resulting from this research.

General Info

US Air Force market research for an Automated Coagulation Analyzer System in Ohio.

Agency

Department Of Defense → FA8601 Aflcmc Pzio

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

Wright Patterson AFB, OH, USA

Set-Aside

NONE

Documents

SOW - Automated Coagulation System (10 Aug 2026)

sow

High

WPAFB CPRR Parts List

specifications

High

FA8601-26-Q-0136SS Sources Sought Instructions

sources-sought

Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

1 update

PhaseClosed

PostedAug 19

Sources Sought

Notice updatedAug 20

The notice description changed.

Response DeadlineAug 25

Deadline has passed

Submission Closed

08/25/2026, 04:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → FA8601 Aflcmc Pzio

Contacts2 people available

OfficeWRIGHT PATTERSON AFB, OH, 45433-5344, USA

Organization / AgencyDepartment Of Defense → FA8601 Aflcmc Pzio

Office AddressWRIGHT PATTERSON AFB, OH, 45433-5344, USA

Contacts

Dametria Walder

contact@example.gov

Claire Hess

contact@example.gov

Full Description

***08/20/2026 - Uploading attachment 3 parts list***

Notice from the United States Air Force, Air Force Life Cycle Management Center (AFLCMC), Installation Contracting Division, Base Support Contracting Branch at Wright-Patterson Air Force Base (WPAFB), Ohio:

The AFLCMC Operational Contracting Branch, Wright-Patterson AFB, Ohio is seeking capabilities packages of potential sources including Small Businesses (SB). This sources sought synopsis is published for market research purposes only, to identify potential sources capable of delivering an Automated Coagulation Analyzer with the capabilities described herein for the Wright-Patterson Medical Center located at Wright Paterson Air Force Base, Ohio (WPAFB).

The Government is seeking capabilities packages from all potential sources, including but not limited to: small business (SB), 8(a) participants, HUBZone Small Business, Economically Disadvantaged Women-Owned Small Business (EDWOSB), Women-Owned Small Business (WOSB), and Service-Disabled Veteran-Owned Small Business (SDVOSB). Firms that respond shall review the attached instructions and technical requirements and submit responses that:

Specify that offered products meet the specifications provided below; and
Provide detailed information to show clear technical compliance.

THIS SOURCES SOUGHT IS FOR MARKET RESEARCH PURPOSES ONLY. THIS IS NOT A REQUEST FOR PROPOSALS/QUOTES.

All interested firms shall submit a response to the Primary Point of Contact, Dametria Walder, demonstrating their capability to provide an Automated Coagulation Analyzer System. Stipulated in Federal Acquisition Regulation (FAR) 15.201, responses to this notice are not considered offers and cannot be accepted by the Government to form a binding contract. A solicitation for this requirement does not exist, therefore, do not request a copy of the solicitation. The decision to solicit for a contract will be solely within the Government's discretion.

The North American Industry Classification System (NAICS) code assigned to this acquisition is 325412 Pharmaceutical Preparation Manufacturing, with a small business size standard of 1300 employees. Firms responding should indicate socio-economic status (8(a) with Graduation Date, SDVOSB, EDWOSB, WOSB, small business, and/or HUBZone). Respondents are further requested to indicate their status as a foreign-owned/foreign-controlled firm and any contemplated use of foreign national employees on this effort. The Government reserves the right to consider a small business set-aside based upon responses hereto for any subsequent action. All prospective contractors must be registered in the System for Award Management (SAM) database to be awarded a Department of Defense (DoD) contract. A small business set-aside decision has not yet been made.

Respondents should note the potential application of Limitations on Subcontracting (FAR 52.219-14) and the Non-Manufacturer Rule (FAR 52.219-33) to a future acquisition that may result from this Sources Sought. Respondents should consider how the primary tasks identified in this notice will be broken out between prime contractor and subcontractors and address subcontracting in their response, if applicable/necessary.

Any information submitted by respondents to this Sources Sought is voluntary. This Sources Sought notice is not to be construed as a commitment by the Government, nor will the Government reimburse any costs associated with the submission of information in response to this notice. Respondents will not be individually notified of the results of any Government assessments. The Government's assessment of the capability statements received will factor into whether any forthcoming solicitation will be conducted as a full and open competition or as a set-aside for small business or any particular small business program.

CAPABILITIES PACKAGE:

All interested firms shall submit a capabilities package for the Automated Coagulation Analyzer System that explicitly demonstrates their capability to provide the required product. The capabilities package should be brief and concise, yet clearly demonstrate an ability to meet the stated requirements. However, the response must not exceed five (5) pages. Capabilities Packages submitted in response to this sources sought synopsis must be received at the following e-mail addresses NOT LATER THAN 25 August 2026 AT 12:00 PM EASTERN DAYLIGHT TIME.

All correspondence sent via email shall contain a subject line that reads Automated Coagulation Analyzer System. If this subject line is not included, the email may not get through email filters at WPAFB. Filters are designed to delete emails without a subject or with a suspicious subject or attachments. Attachments with files ending in .zip or .exe are not allowable and will be deleted. Ensure only .pdf, .doc, .docx, .xsls or .xls documents are attached to your email. All other attachments may be deleted.

Responses shall be submitted via email to the following addresses: dametria.walder@us.af.mil and claire.hess@us.af.mil

Please direct all questions concerning this acquisition to Dametria Walder at dametria.walder@us.af.mil and include the necessary subject line indicated above.

Attachments: